Organogenesis (NASDAQ:ORGO) Announces Quarterly Earnings Results

Organogenesis (NASDAQ:ORGO) released its earnings results on Thursday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%. The firm had revenue of $45.46 million during the quarter, compared to analysts’ expectations of $52.10 million.

Here are the key takeaways from Organogenesis’ conference call:

• Third-quarter net product revenue fell 70% year over year, though it rose 6% sequentially. The company lowered its 2026 revenue outlook to $179 million–$200 million and described the market recovery as more measured than previously expected.
• Organogenesis said it gained market share, with claims data indicating its share increased more than 30% versus Q1, and reported sequential sales growth across Advanced Wound Care and Surgical & Sports Medicine. Management believes the market has bottomed, while acknowledging that low-cost inventory and ongoing customer uncertainty may continue to affect recovery.
• The company reported a $29.6 million GAAP net loss and had $26.9 million in cash and restricted cash at quarter-end, down from $94.3 million at year-end 2025. Management expects further sequential improvement in adjusted EBITDA, but positive adjusted EBITDA in Q4 is anticipated only at the high end of its outlook.
• The FDA review of Amnuvx faces a longer timeline after the agency identified 18 items requiring remediation at the Norwood facility and requested additional clinical information. The company expects remediation to finish by September 2027, estimates an $8 million total cost, and said the PDUFA target date will be extended from April 2027.

Organogenesis Trading Down 3.2%

Shares of ORGO traded down $0.03 during mid-day trading on Friday, reaching $0.81. The company had a trading volume of 907,109 shares, compared to its average volume of 997,199. Organogenesis has a fifty-two week low of $0.73 and a fifty-two week high of $7.08. The firm has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $2.31. The stock has a market cap of $104.64 million, a price-to-earnings ratio of -0.67 and a beta of 1.48. The company has a current ratio of 3.52, a quick ratio of 3.00 and a debt-to-equity ratio of 0.07.

Analysts Set New Price Targets

Several research firms have recently issued reports on ORGO. Weiss Ratings cut Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 19th. Wall Street Zen lowered Organogenesis from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Truist Financial reduced their target price on Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $4.33.

More Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Management expects to reduce annual operating expenses by approximately $45 million, which could help lower costs. Third-quarter net product revenue also rose 6% from the prior quarter, signaling some sequential recovery. Article: Organogenesis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The earnings call was characterized as showing signs of recovery alongside major setbacks; the sequential revenue improvement and cost-cutting plan offer possible offsets, but do not erase the weak quarterly results. Article: Organogenesis Earnings Call Signals Recovery Amid Major Setbacks
• Negative Sentiment: Organogenesis reported a third-quarter loss of $0.25 per share, wider than the $0.18 loss analysts expected. Revenue of $45.46 million also missed the $52.10 million consensus estimate, raising concerns about near-term performance. Article: Organogenesis Reports Third Quarter 2026 Financial Results

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.